Objective: We performed a population-based analysis to evaluate changes in patterns of radiation therapy (RT) usage after breast-conserving surgery (BCS) and outcomes among women aged 70 years or older with stage I breast cancer.
Methods: We used the Surveillance, Epidemiology and End Results database to identify 33,350 women aged 70 years or older diagnosed from 1990 to 2008 with stage I invasive ductal breast cancer treated with BCS. Patients were stratified by estrogen receptor (ER) status, and classified by RT modality: external beam RT, brachytherapy (BT), other, or none. Usage frequency for each modality was tabulated from 2000 to 2008 subset. Predictors of omission of RT and use of BT were determined by multiple logistic regression. Cox proportional hazard models were created to evaluate the effect of RT usage on breast cancer-specific mortality.
Results: The use of external beam RT decreased during 2000 to 2008. Omission of RT after BCS increased in patients with ER-positive tumors, whereas use of BT increased for both ER-positive and ER-negative tumors. Predictors for the use of BT were later year of diagnosis, metropolitan residence, and highest income quartile. Omission of use of any RT was associated with increased risk of breast cancer-specific mortality among both ER-positive and ER-negative cancers, with greater effect in ER-negative women.
Conclusions: Among older women with stage I breast cancer treated with BCS, use of any RT has been omitted more frequently and BT utilized more often. Further studies are necessary to evaluate potential under-utilization of RT, particularly among women with ER-negative tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/COC.0b013e318271b326 | DOI Listing |
JAMA Netw Open
December 2024
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown if these associations occur in ER-specific CBC.
Objective: To determine the association of deleterious germline variants in breast cancer susceptibility genes with ER-specific CBC development and whether ER status of the first primary breast cancer modifies these associations.
Design, Setting, And Participants: This case-control study included CBC cases and matched unilateral breast cancer controls from The Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population-based case-control study.
Breast Cancer Res Treat
January 2025
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, 34390, Faith, Istanbul, Turkey.
Purpose: This study aimed to determine estrogen receptor (ER) expression in stromal cells in postchemotherapy tumor bed (PCTB) and its relationship with tumor regression and tumor characteristics.
Methods: The study included 490 breast cancer patients who received neoadjuvant chemotherapy (NAC). We performed ER in stromal cells in all resection specimens and available pre-treatment core biopsy materials of 299 patients immunohistochemically.
Sci Rep
January 2025
Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
Bcl-2, a key regulator of cellular apoptosis, is typically linked to adverse prognosis in solid tumors due to its inhibition of apoptotic cell death and promotion of cellular proliferation, leading to tumor progression. However, studies on Bcl-2 in breast cancer have shown inconsistent results, with some indicating favorable outcomes. This study aims to determine the subtype-specific role of Bcl-2 in breast cancer.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road., Pathumwan, Bangkok, 10330, Thailand.
Zoledronic acid (ZA), a bisphosphonate, is commonly used in breast cancer patients with bone metastases to treat hypercalcemia and osteolysis. Recent studies showed the anti-cancer effects of ZA in breast cancer. This study further explored the synergistic effects of sequential and nonsequential ZA and doxorubicin (DOX) administration on estrogen receptor (ER)-positive and -negative breast cancer cell lines.
View Article and Find Full Text PDFBreast J
January 2025
Department of Breast Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, China.
We aimed to investigate whether estrogen receptor (ER) status affects the predictive role of the human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) score on the efficacy of neoadjuvant treatment for HER2-positive breast cancer. This retrospective study comprised 167 individuals diagnosed with HER2-positive invasive breast cancer who had undergone neoadjuvant treatment and surgery. Uni- and multivariable logistic regression analyses were performed on the relationship between the HER2 IHC score and total pathological complete response (tpCR), breast pathological complete response (bpCR), or axillary partial response (apCR).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!